Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “KT501 is a monoclonal antibody that depletes B cells including plasma cells by targeting CD19, BCMA and CD3.”In the company’s words, NCT07234773 on ClinicalTrials.gov
- Tested for
- Rheumatoid Arthritis (RA)
- Main trialPhase 1
- “This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).”In the company’s words, NCT07234773 on ClinicalTrials.gov
Other drugs for Rheumatoid Arthritis (RA)
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up1
- Feb 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Feb 2027 | A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026